APLT News and Press, Applied Therapeutics Inc. From 01/23/20

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

2019 was almost  the record year for IPOs and venture capital (VC) investors. The year 2018 was No. 1 for the number of new unicorns, the total dollar amount of VC investment, and a few other metrics; 2019 came in second in many of these categories. Does this mean 2018 was the p...

Applied Therapeutics (NASDAQ: APLT ) announces a public offering of 1.75M common shares. Underwriters' over-allotment will be an additional 262.5K shares. More news on: Applied Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

Applied Therapeutics, Inc. ( APLT ) increased 34% to $35.18 on Wednesday after announcing positive topline results from the Phase 2 portion of its ACTION-Galactosemia study of AT-007 for adult Galactosemia patients. The data was so compelling according to the company that it plans to apply f...

Shares of Applied Therapeutics (NASDAQ: APLT) are up 29% at 12:38 p.m. EST after the biotech reported positive data from a phase 2 clinical trial of AT-007 in galactosemia patients. People with galactosemia can't properly process a sugar called galactose, which is found in food and also mad...

Gainers: ShiftPixy (NASDAQ: PIXY ) +162% . More news on: ShiftPixy, Inc., Wah Fu Education Group Limited, Verastem, Inc., Stocks on the move, Read more ...

ShiftPixy (NASDAQ: PIXY ) +199%  on completing recapitalization . More news on: ShiftPixy, Inc., Applied Therapeutics, Inc., Mechel PAO, Stocks on the move, Read more ...

Thinly traded micro cap Applied Therapeutics (NASDAQ: APLT ) is up  21%  premarket on average volume in reaction to positive results from a Phase 2 clinical trial, ACTION-Galactosemia , evaluating candidate AT-007 in adult patients with galactosemia , a rare inherited metabol...

AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p<0.01) AT-007 was well-tolerated; no drug-related adverse events reported at any dose to date Applied Therapeutics expects to file for regulatory appr...